"Regression to the truth": lessons learned from negative IPF trials.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with limited treatment options. Despite the approval of pirfenidone and nintedanib that slow disease progression, IPF remains a disease with poor survival. Promising therapeutic candidates were tested as potential treatments for IPF and w...

Full description

Bibliographic Details

Published in:	Breathe Vol. 21; no. 2; pp. 1 - 8
Main Authors:	Trachalaki, Athina, Lindahl, Anna L., Petrarulo, Simone, Margaritopoulos, George A.
Format:	questions and answers tables/charts Journal Article
Published:	European Respiratory Society Apr2025
Online Access:	View this record in EBSCOhost